Drug Profile
BCX 5
Alternative Names: CI 1000; PD 141955Latest Information Update: 28 Jun 1999
Price :
$50
*
At a glance
- Originator Pfizer
- Developer BioCryst Pharmaceuticals; Pfizer
- Class
- Mechanism of Action Purine nucleoside phosphorylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 28 Jun 1999 Discontinued-I for Transplant rejection in USA (Unknown route)
- 22 Jan 1996 Phase-I clinical trials for Transplant rejection in USA (Unknown route)